MCID: END085
MIFTS: 43

Endometrial Serous Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Serous Adenocarcinoma

MalaCards integrated aliases for Endometrial Serous Adenocarcinoma:

Name: Endometrial Serous Adenocarcinoma 12 15 17 70
Uterine Corpus Serous Adenocarcinoma 12
Uterine Papillary Serous Carcinoma 12
Uterine Serous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5750
NCIt 50 C27838
UMLS 70 C0854924 C1336921

Summaries for Endometrial Serous Adenocarcinoma

Disease Ontology : 12 A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia.

MalaCards based summary : Endometrial Serous Adenocarcinoma, also known as uterine corpus serous adenocarcinoma, is related to ovarian serous carcinoma and estrogen excess. An important gene associated with Endometrial Serous Adenocarcinoma is MIR455 (MicroRNA 455), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Letrozole and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include lymph node, uterus and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Endometrial Serous Adenocarcinoma

Diseases related to Endometrial Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 262)
# Related Disease Score Top Affiliating Genes
1 ovarian serous carcinoma 30.4 WT1 TP53 KRAS BRCA1
2 estrogen excess 30.3 PTEN PGR ELAPOR1
3 primary peritoneal carcinoma 30.2 TP53 PGR ERBB2 BRCA1
4 papillary adenocarcinoma 30.2 TP53 PGR ERBB2 BRCA1
5 cervix carcinoma 30.1 TP53 PIK3CA PGR MIR455 ERBB2
6 hereditary breast ovarian cancer syndrome 30.0 TP53 PTEN KRAS ERBB2 BRCA1
7 papilloma 29.9 TP53 PTEN KRAS ERBB2
8 papillary serous adenocarcinoma 29.9 WT1 TP53 PGR KRAS BRCA1
9 in situ carcinoma 29.8 TP53 PTEN PIK3CA PGR ERBB2 BRCA1
10 li-fraumeni syndrome 29.7 TP53 PTEN KRAS ERBB2 BRCA1
11 endometrial hyperplasia 29.7 TP53 PTEN PGR KRAS ARID1A
12 endometrial adenocarcinoma 29.6 TP53 PTEN PGR KRAS ERBB2
13 gastrointestinal stromal tumor 29.6 WT1 TP53 PTEN KRAS ERBB2
14 adenocarcinoma 29.3 TP53 PTEN POLE PIK3CA KRAS ERBB2
15 wilms tumor 1 29.3 WT1 TP53 PGR KRAS FBXW7 ERBB2
16 lynch syndrome 29.3 TP53 PTEN POLE PIK3CA KRAS BRCA1
17 uterine carcinosarcoma 29.1 TP53 PTEN PPP2R1A POLE PIK3CA PGR
18 carcinosarcoma 29.1 TP53 PTEN PPP2R1A POLE PIK3CA PGR
19 endometrioid ovary carcinoma 29.0 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
20 serous cystadenocarcinoma 28.0 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
21 ovarian cancer 27.8 WT1 TP53 PTEN PIK3CA PGR MIR34B
22 endometrial cancer 27.5 WT1 TP53 PTEN POLE PIK3CA PGR
23 breast cancer 27.2 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
24 papillary carcinoma 10.4
25 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
26 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
27 breast juvenile papillomatosis 10.4 PIK3CA ERBB2
28 parotid gland cancer 10.4 TP53 ERBB2
29 familiar ovarian carcinoma 10.4 PIK3CA BRCA1
30 polyploidy 10.3 TP53 AURKB
31 clear cell adenofibroma 10.3 PPP2R1A PIK3CA ARID1A
32 ruvalcaba syndrome 10.3 PTEN BRCA1
33 penile benign neoplasm 10.3 TP53 PIK3CA
34 lung oat cell carcinoma 10.3 TP53 PTEN PIK3CA
35 gallbladder adenocarcinoma 10.3 TP53 PIK3CA ERBB2
36 senile angioma 10.3 MIR455 CCNE1
37 ovarian clear cell adenocarcinoma 10.3 TP53 PIK3CA ARID1A
38 clear cell adenocarcinoma 10.3 TP53 PIK3CA ARID1A
39 fallopian tube carcinosarcoma 10.3 WT1 TP53
40 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 PIK3CA FBXW7
41 anal squamous cell carcinoma 10.3 TP53 PIK3CA FBXW7
42 epithelial-myoepithelial carcinoma 10.3 TP53 PIK3CA FBXW7
43 neurofibroma 10.3 TP53 PTEN ERBB2
44 bartholin's gland adenoma 10.2 TP53 PGR
45 prostate squamous cell carcinoma 10.2 TP53 PIK3CA CCNE1
46 bartholin's gland benign neoplasm 10.2 TP53 PGR
47 vestibular gland benign neoplasm 10.2 TP53 PGR
48 glassy cell carcinoma of the cervix 10.2 PGR ERBB2
49 breast duct papilloma 10.2 PTEN PGR
50 breast intraductal papillomatosis 10.2 PGR ERBB2

Graphical network of the top 20 diseases related to Endometrial Serous Adenocarcinoma:



Diseases related to Endometrial Serous Adenocarcinoma

Symptoms & Phenotypes for Endometrial Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 47)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.61 AURKA PIK3CA KRAS
2 Decreased viability GR00055-A-2 10.61 AURKA PIK3CA KRAS
3 Decreased viability GR00055-A-3 10.61 KRAS
4 Decreased viability GR00106-A-0 10.61 KRAS
5 Decreased viability GR00173-A 10.61 AURKB
6 Decreased viability GR00221-A-1 10.61 AURKA AURKB PIK3CA KRAS
7 Decreased viability GR00221-A-2 10.61 AURKA AURKB CDC42SE2 PIK3CA BRCA1 KRAS
8 Decreased viability GR00221-A-3 10.61 ERBB2 BRCA1
9 Decreased viability GR00221-A-4 10.61 AURKA AURKB CDC42SE2 ERBB2 PIK3CA
10 Decreased viability GR00231-A 10.61 AURKA
11 Decreased viability GR00249-S 10.61 AURKA AURKB CDC42SE2
12 Decreased viability GR00301-A 10.61 BRCA1 KRAS
13 Decreased viability GR00381-A-1 10.61 KRAS
14 Decreased viability GR00402-S-2 10.61 AURKA PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-1 9.95 POLE
16 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.95 KRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 POLE
18 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.95 BRCA1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.95 BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.95 PTEN
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.95 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.95 ERBB2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.95 ARID1A BRCA1 ERBB2 POLE PTEN
24 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.95 ARID1A
25 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.95 ARID1A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.95 ARID1A
27 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.95 POLE
28 Increased shRNA abundance (Z-score > 2) GR00366-A-204 9.95 BRCA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.95 ERBB2 POLE
30 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.95 BRCA1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.95 ARID1A
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 PTEN
33 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.95 KRAS
34 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.95 ERBB2 POLE
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 PTEN
36 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 ARID1A
37 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.95 ERBB2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.95 ERBB2 KRAS POLE PTEN
39 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.95 PTEN
40 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.95 ARID1A
41 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 ERBB2 POLE
42 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.95 ERBB2 POLE PTEN
43 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.95 POLE
44 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.95 PTEN
45 Decreased cell proliferation GR00353-A 9.5 AURKA CDC42SE2 ERBB2
46 Increased cell death in HCT116 cells GR00103-A-0 9.35 AURKA CHD4 FBXW7 PIK3CA PPP2R1A
47 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN WT1

MGI Mouse Phenotypes related to Endometrial Serous Adenocarcinoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
2 cellular MP:0005384 10.42 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
3 embryo MP:0005380 10.38 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
4 mortality/aging MP:0010768 10.33 ARID1A AURKA AURKB BRCA1 CCNE1 CHD4
5 growth/size/body region MP:0005378 10.32 ARID1A AURKA AURKB BRCA1 CCNE1 ERBB2
6 endocrine/exocrine gland MP:0005379 10.3 ARID1A BRCA1 CCNE1 CHD4 ERBB2 FBXW7
7 immune system MP:0005387 10.29 ARID1A BRCA1 CCNE1 CHD4 ELAPOR1 FBXW7
8 hematopoietic system MP:0005397 10.27 ARID1A BRCA1 CCNE1 CHD4 ELAPOR1 FBXW7
9 integument MP:0010771 10.2 AURKB BRCA1 CCNE1 ERBB2 FBXW7 KRAS
10 neoplasm MP:0002006 10.2 ARID1A AURKA AURKB BRCA1 CCNE1 ERBB2
11 limbs/digits/tail MP:0005371 10.03 AURKA BRCA1 ELAPOR1 ERBB2 KRAS PGR
12 muscle MP:0005369 10.02 ARID1A BRCA1 ERBB2 KRAS PGR PIK3CA
13 no phenotypic analysis MP:0003012 9.91 ARID1A AURKA AURKB CHD4 KRAS PGR
14 normal MP:0002873 9.9 ARID1A BRCA1 CCNE1 ERBB2 FBXW7 KRAS
15 reproductive system MP:0005389 9.73 ARID1A AURKB BRCA1 CCNE1 ELAPOR1 ERBB2
16 skeleton MP:0005390 9.32 ARID1A BRCA1 CCNE1 ELAPOR1 ERBB2 KRAS

Drugs & Therapeutics for Endometrial Serous Adenocarcinoma

Drugs for Endometrial Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
2
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
3 Estrogens Phase 2, Phase 3
4 Immunosuppressive Agents Phase 2, Phase 3
5 Hormone Antagonists Phase 2, Phase 3
6 Hormones Phase 2, Phase 3
7 Estrogen Receptor Antagonists Phase 2, Phase 3
8 Aromatase Inhibitors Phase 2, Phase 3
9 Estrogen Antagonists Phase 2, Phase 3
10
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
11
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
12
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
13
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
14
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
15
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
16 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
17 Mitogens Phase 2
18 Tubulin Modulators Phase 2
19 Albumin-Bound Paclitaxel Phase 2
20 Antimitotic Agents Phase 2
21 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
22 Protein Kinase Inhibitors Phase 1, Phase 2
23
Olaparib Approved Phase 1 763113-22-0 23725625
24
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
25
Camptothecin Experimental Phase 1 7689-03-4
26 Immunologic Factors Phase 1
27 Immunoconjugates Phase 1
28 topoisomerase I inhibitors Phase 1
29 Antineoplastic Agents, Immunological Phase 1
30
Levoleucovorin Approved, Investigational 68538-85-2 149436
31
Progesterone Approved, Vet_approved 57-83-0 5994
32
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
33 Vitamin B9
34 Folate
35 Vitamin B Complex

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
2 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
3 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
4 A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma Recruiting NCT02491099 Phase 2 Afatinib
5 A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma Recruiting NCT04590248 Phase 2 Adavosertib
6 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
7 Trial of Maintenance With Niraparib in Patients With Stage III, Stage IV or Platinum-sensitive Recurrent Uterine Serous Carcinoma Recruiting NCT04080284 Phase 2 Niraparib
8 A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma Not yet recruiting NCT04814108 Phase 2 ZN-c3
9 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Not yet recruiting NCT04030000 Phase 1, Phase 2 Paclitaxel/Carboplatin
10 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Terminated NCT02112552 Phase 2 Paclitaxel;Carboplatin
11 A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC) Terminated NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
12 A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma Active, not recruiting NCT03325634 Phase 1
13 A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies Not yet recruiting NCT04585958 Phase 1 Olaparib
14 Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers Completed NCT02315469
15 A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma Not yet recruiting NCT04494113 Early Phase 1 Triapine
16 The Role of Synuclein-gamma (SNCG) in the Carcinogenesis of Uterine Papillary Serous Carcinoma Not yet recruiting NCT01344837

Search NIH Clinical Center for Endometrial Serous Adenocarcinoma

Genetic Tests for Endometrial Serous Adenocarcinoma

Anatomical Context for Endometrial Serous Adenocarcinoma

MalaCards organs/tissues related to Endometrial Serous Adenocarcinoma:

40
Lymph Node, Uterus, Breast, Thyroid, Cervix

Publications for Endometrial Serous Adenocarcinoma

Articles related to Endometrial Serous Adenocarcinoma:

(show top 50) (show all 244)
# Title Authors PMID Year
1
Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. 61
33077919 2021
2
Controversies in the Management of Early-stage Serous Endometrial Cancer. 61
33622859 2021
3
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. 61
33705205 2021
4
Uterine Serous Carcinoma Responds to the WEE1 Inhibitor Adavosertib. 61
33771773 2021
5
HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma. 61
33739786 2021
6
A 4-gene signature predicts prognosis of uterine serous carcinoma. 61
33579221 2021
7
The Impact of Adjuvant Management Strategies on Outcomes in Women With Early Stage Uterine Serous Carcinoma. 61
33786214 2021
8
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. 61
33160694 2021
9
Incidence of omental metastasis in uterine serous carcinoma: study protocol for a systematic review and meta-analysis. 61
33455937 2021
10
The role of lymphadenectomy in patients with stage III&IV uterine serous carcinoma: Results of multicentric Turkish study. 61
33453448 2021
11
[Diagnosis, treatment and prognosis of uterine serous carcinoma]. 61
33355760 2020
12
Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer. 61
33295973 2020
13
Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer. 61
33305084 2020
14
Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma. 61
32900500 2020
15
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. 61
32709539 2020
16
xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma. 61
32782585 2020
17
Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma. 61
32808495 2020
18
Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma - an anachronism? 61
32808502 2020
19
Abdominopelvic Metastasis of Endometrial Serous Carcinoma Initially Misdiagnosed as Early-Stage Low-Grade Endometrioid Carcinoma: The Importance of Recognizing Minimal Uterine Serous Carcinoma. 61
33564295 2020
20
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. 61
32601075 2020
21
Thrombocytosis as a Biomarker in Type II, Non-Endometrioid Endometrial Cancer. 61
32842701 2020
22
Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium. 61
32675056 2020
23
Fallopian tube abnormalities in uterine serous carcinoma. 61
32409160 2020
24
Superior vena cava syndrome associated with uterine serous carcinoma. 61
32577490 2020
25
Stage III uterine serous carcinoma: modern trends in multimodality treatment. 61
32266802 2020
26
Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report. 61
32300630 2020
27
Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression. 61
32258332 2020
28
A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy. 61
32067813 2020
29
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report. 61
32215315 2020
30
Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. 61
32140533 2020
31
Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site. 61
31165997 2020
32
Pathogenesis and Clinical Management of Uterine Serous Carcinoma. 61
32183290 2020
33
Adjuvant chemotherapy in endometrial cancer. 61
31950214 2020
34
Distant recurrence in a patient with polyp-confined stage IA serous endometrial carcinoma treated with adjuvant chemotherapy: A case report and review of literature. 61
31890830 2020
35
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. 61
32190072 2020
36
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. 61
31833974 2020
37
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. 61
31839338 2020
38
Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. 61
31906456 2020
39
Metabolic syndrome affects the long-term survival of patients with non-endometrioid carcinoma of the uterine corpus. 61
31560127 2020
40
Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. 61
31815745 2020
41
Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma. 61
31739992 2020
42
Breast metastases: A rare manifestation of advanced uterine serous carcinoma. 61
31656850 2019
43
The role of omentectomy in the surgical treatment of uterine serous carcinoma. 61
31517308 2019
44
Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. 61
31228268 2019
45
Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer. 61
31320996 2019
46
Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation. 61
30896884 2019
47
Synchronous renal and para-aortic metastasis in a uterine serous carcinoma: A case review and clinical considerations. 61
30740508 2019
48
Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience. 61
30122267 2019
49
Sectioning and extensively examining the fimbriated end (SEE-FIM) of the fallopian tube in routine practices, is it worth the effort? 61
30506766 2019
50
[Uterine serous carcinoma accompany with serous endometrial intraepithelial carcinoma and papillary proliferation of the endometrium: report of a case]. 61
30641649 2019

Variations for Endometrial Serous Adenocarcinoma

Copy number variations for Endometrial Serous Adenocarcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 52344 11 16200000 21700000 Copy number SAA1 Uterine serous papillary cancer

Expression for Endometrial Serous Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Serous Adenocarcinoma.

Pathways for Endometrial Serous Adenocarcinoma

Pathways related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TP53 PTEN PPP2R1A KRAS ERBB2 CCNE1
2
Show member pathways
13.81 TP53 PTEN PPP2R1A PGR ERBB2 CHD4
3
Show member pathways
12.87 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
4
Show member pathways
12.85 TP53 PTEN PPP2R1A CHD4 CCNE1 BRCA1
5 12.83 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
6
Show member pathways
12.75 TP53 PTEN PPP2R1A PIK3CA KRAS ERBB2
7
Show member pathways
12.72 TP53 PTEN PIK3CA KRAS ERBB2
8
Show member pathways
12.7 TP53 POLE FBXW7 CCNE1 BRCA1
9
Show member pathways
12.7 TP53 PTEN PPP2R1A PIK3CA KRAS ERBB2
10
Show member pathways
12.62 TP53 PTEN PIK3CA KRAS ERBB2
11
Show member pathways
12.55 TP53 PTEN PIK3CA KRAS ERBB2 CCNE1
12
Show member pathways
12.5 TP53 PTEN PIK3CA KRAS ERBB2
13 12.46 TP53 PPP2R1A CCNE1 BRCA1 AURKB AURKA
14
Show member pathways
12.43 TP53 PIK3CA KRAS ERBB2
15
Show member pathways
12.37 TP53 PTEN MIR34B CCNE1 BRCA1
16
Show member pathways
12.31 TP53 PTEN PIK3CA ERBB2
17 12.31 TP53 PTEN PIK3CA KRAS CCNE1
18 12.3 TP53 PIK3CA KRAS ERBB2
19
Show member pathways
12.29 PPP2R1A PIK3CA PGR KRAS CCNE1 AURKA
20
Show member pathways
12.28 TP53 PTEN PIK3CA PGR KRAS ERBB2
21 12.27 TP53 PIK3CA KRAS CHD4 CCNE1
22
Show member pathways
12.26 TP53 PTEN CCNE1 BRCA1
23 12.25 TP53 PTEN PIK3CA MIR34B KRAS ERBB2
24
Show member pathways
12.23 TP53 PTEN PIK3CA KRAS ERBB2
25
Show member pathways
12.22 PGR FBXW7 CCNE1 BRCA1
26 12.18 PTEN KRAS ERBB2 AURKA
27
Show member pathways
12.13 PTEN PIK3CA KRAS ERBB2
28 12.13 TP53 PTEN PIK3CA KRAS CCNE1
29 12.11 TP53 PTEN KRAS BRCA1 AURKA
30 11.97 TP53 PTEN PPP2R1A PIK3CA KRAS
31 11.96 TP53 PTEN KRAS CCNE1
32
Show member pathways
11.94 PIK3CA PGR KRAS ERBB2
33 11.94 TP53 PTEN PIK3CA KRAS ERBB2
34 11.86 TP53 PTEN PIK3CA CCNE1
35 11.84 PTEN CCNE1 BRCA1
36 11.83 TP53 POLE CCNE1
37
Show member pathways
11.82 TP53 CCNE1 BRCA1
38 11.74 TP53 KRAS ERBB2
39 11.71 TP53 PIK3CA ERBB2 BRCA1
40 11.59 TP53 PTEN PIK3CA
41 11.56 TP53 PTEN PIK3CA KRAS ERBB2
42 11.55 TP53 MIR34B CCNE1
43 11.5 TP53 PTEN BRCA1
44 11.47 TP53 CCNE1 BRCA1
45 11.31 TP53 CCNE1 BRCA1
46 11.28 PTEN PIK3CA KRAS
47 11.26 TP53 CCNE1 BRCA1
48 11.16 TP53 BRCA1 AURKB AURKA
49 11.02 TP53 CCNE1 BRCA1
50 10.99 TP53 PTEN PIK3CA FBXW7 ERBB2 BRCA1

GO Terms for Endometrial Serous Adenocarcinoma

Cellular components related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.1 WT1 TP53 PTEN PPP2R1A POLE PGR
2 cytoplasm GO:0005737 9.83 WT1 TP53 PTEN PPP2R1A PIK3CA PGR
3 nucleoplasm GO:0005654 9.4 WT1 TP53 PTEN POLE PGR FBXW7
4 chromosome passenger complex GO:0032133 9.16 AURKB AURKA

Biological processes related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.62 WT1 TP53 PTEN ERBB2
2 regulation of protein stability GO:0031647 9.54 PTEN KRAS AURKA
3 cellular response to UV GO:0034644 9.43 TP53 FBXW7 AURKB
4 positive regulation of gene expression GO:0010628 9.43 WT1 TP53 PTEN KRAS ERBB2 BRCA1
5 phosphatidylinositol 3-kinase signaling GO:0014065 9.33 PTEN PIK3CA ERBB2
6 regulation of signal transduction by p53 class mediator GO:1901796 9.02 TP53 CHD4 BRCA1 AURKB AURKA

Molecular functions related to Endometrial Serous Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.43 WT1 TP53 POLE PGR CHD4 BRCA1
2 histone serine kinase activity GO:0035174 8.62 AURKB AURKA

Sources for Endometrial Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....